Regulus Therapeutics Inc - Company Profile
Powered by 
All the sales intelligence you need on Regulus Therapeutics Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Regulus Therapeutics Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Regulus Therapeutics Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Regulus Therapeutics Inc (Regulus), a subsidiary of Novartis AG, is a biotechnology company focused on developing oligonucleotide therapeutics aimed at inhibiting dysregulated microRNA targets. The company offers researching and developing treatments for genetically based orphan diseases, particularly orphan kidney diseases such as Autosomal Dominant Polycystic Kidney Disease (ADPKD). Its pipeline product include RGLS8429 which treats ADPKD. The company's therapeutics are designed for patients with high unmet medical needs, particularly those affected by genetic kidney diseases. Regulus collaborates with industry leaders Alnylam and Ionis for intellectual property related to oligonucleotide-based therapeutics and others. Regulus Therapeutics is headquartered in San Diego, California, the US.
Headquarters
United States of America
Address
4224 Campus Point Court, Suite 210, San Diego, California, 92121
Website
www.regulusrx.com
Telephone
1 858 2026300
No of Employees
34
Industry
Pharmaceuticals and Healthcare
Regulus Therapeutics Inc premium industry data and analytics
Products and Services
| Products | Services |
|---|---|
| Product: | Clinical Trials |
| Pipeline Product: | |
| ADPKD- Autosomal Dominant Polycystic Kidney Disease |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Ownership Changes | In June, the company was acquired by Novartis, a pharmaceutical company. |
| 2020 | Contracts/Agreements | In December, the company entered into a collaboration with Bio-Techne to support biomarker assay development and biomarker analysis to develop RGLS4326 for the kidney disease treatment. |
| 2015 | Contracts/Agreements | In November, Regulus Therapeutics Inc. through its collaboration and formulation development agreement with GlaxoSmithKline have expanded the development of RG-101. |
Competitor Comparison
| Key Parameters | Regulus Therapeutics Inc | Ionis Pharmaceuticals Inc | Arrowhead Pharmaceuticals Inc | Genzyme Corp |
|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America |
| City | San Diego | Carlsbad | Pasadena | Cambridge |
| State/Province | California | California | California | Massachusetts |
| No. of Employees | 34 | 1,069 | 711 | - |
| Entity Type | Private | Public | Public | Private |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Stelios Papadopoulos, Ph.D. | Chairman | Executive Board | - | 75 |
| Jay Hagan | Chief Executive Officer; Director | Executive Board | - | 55 |
| Preston S. Klassen, MD | Research and Development; President; Director | Executive Board | - | 55 |
| Cris Calsada | Chief Financial Officer | Senior Management | - | - |
| Moh Ahmadian, Ph.D. | Vice President - Chemistry and Pharmaceutical Development | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer